嗜酸性粒细胞型慢性阻塞性肺疾病的研究进展

doi:10.19983/j.issn.2096-8493.20210164

摘要/Abstract

摘要：

慢性阻塞性肺疾病(简称“慢阻肺”)是常见的慢性气道炎症性疾病,但其发病机制十分复杂,尚无细胞和分子机制的确切研究。气道炎症是其可治疗特征之一,但目前的诊断方法无法体现此类患者气道炎症异质性的特点,治疗局限性明显。近年来,大量的临床试验表明,血嗜酸性粒细胞水平与慢阻肺的反应、恶化风险、病亡率和住院时间密切相关,但作用机制还不甚清晰。因此,笔者从嗜酸性粒细胞型慢阻肺的形成过程、诊断及传统糖皮质激素和新的靶向治疗等几个方面进行综述,为嗜酸性粒细胞作为慢阻肺新的潜在生物标志物和可治疗特征提供参考。

关键词: 嗜酸性细胞, 肺疾病,慢性阻塞性, 个体化医学

Abstract:

Chronic obstructive pulmonary disease (COPD) is a common chronic airway inflammatory disease with complex pathogenesis, and cellular or molecular mechanisms remain unknown. Airway inflammation is one of the treatable features, however, current diagnostic methods can not reflect the heterogeneity of airway inflammation in such patients, and the treatment limitations are obvious. In recent years, in large number of clinical trials, it has been a shown that the level of blood eosinophils is closely related to COPD response, deterioration risk, mortality and length of stay in the hospital of COPD, but the mechanism is not very clear. Therefore, the author reviewed the formation process, diagnosis, traditional glucocorticoids and new target therapy of eosinophilic COPD, to provide reference for eosinophils as a new potential biomarker and treatable feature of COPD.

Key words: Oxyphil cells, Pulmonary disease,chronic obstructive, Individualized medicine

中图分类号:

R563.3
R559

曾子航, 陈燕, 龙颖姣. 嗜酸性粒细胞型慢性阻塞性肺疾病的研究进展[J]. 结核与肺部疾病杂志, 2022, 3(1): 50-54. doi: 10.19983/j.issn.2096-8493.20210164

ZENG Zi-hang, CHEN Yan, LONG Ying-jiao. Research progress of eosinophilic chronic obstructive pulmonary disease[J]. Journal of Tuberculosis and Lung Disease, 2022, 3(1): 50-54. doi: 10.19983/j.issn.2096-8493.20210164

参考文献 60

[1]	James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990—2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7. doi: 10.1016/S0140-6736(18)32279-7 URL
[2]	Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980—2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. doi: 10.1016/S0140-6736(18)32203-7 URL
[3]	Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet, 2018, 391(10131):1706-1717. doi: 10.1016/S0140-6736(18)30841-9. doi: 10.1016/S0140-6736(18)30841-9 URL
[4]	Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J, 2016, 47(2):410-419. doi: 10.1183/13993003.01359-2015. doi: 10.1183/13993003.01359-2015 pmid: 26828055
[5]	Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarke? Lancet Respir Med, 2017, 5(9):747-759. doi: 10.1016/S2213-2600(17)30217-5. doi: 10.1016/S2213-2600(17)30217-5 URL
[6]	Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med, 2017, 195(5):557-582. doi: 10.1164/rccm.201701-0218PP. doi: 10.1164/rccm.201701-0218PP URL
[7]	MacDonald MI, Osadnik CR, Bulfin L, et al. Low and high blood eosinophil counts as biomarkers in hospitalized acute exacerbations of COPD. Chest, 2019, 156(1):92-100. doi: 10.1016/j.chest.2019.02.406. doi: S0012-3692(19)30822-0 pmid: 30978330
[8]	Barnes PJ. Inflammatory endotypes in COPD. Allergy, 2019, 74(7):1249-1256. doi: 10.1111/all.13760. doi: 10.1111/all.13760 pmid: 30834543
[9]	Rutgers SR, Timens W, Kaufmann HF, et al. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J, 2000, 15(1):109-115. doi: 10.1183/09031936.00.15110900. doi: 10.1183/09031936.00.15110900 pmid: 10678630
[10]	Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J, 2014, 44(6):1697-1700. doi: 10.1183/09031936.00162414. doi: 10.1183/09031936.00162414 pmid: 25323230
[11]	Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med, 2011, 184(6):662-671. doi: 10.1164/rccm.201104-0597OC. doi: 10.1164/rccm.201104-0597OC URL
[12]	Ko FWS, Chan KP, Ngai J, et al. Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations. Respirology, 2020, 25(3):259-266. doi: 10.1111/resp.13660. doi: 10.1111/resp.13660 URL
[13]	Couillard S, Larivée P, Courteau J, et al. Eosinophils in COPD Exacerbations Are Associated With Increased Readmissions. Chest, 2017, 151(2):366-373. doi: 10.1016/j.chest.2016.10.003. doi: S0012-3692(16)60762-6 pmid: 27746201
[14]	Gursel G, Turktas H, Gokcora N, et al. Comparison of sputum and serum eosinophil cationic protein (ECP) levels in nonatopic asthma and chronic obstructive pulmonary disease. J Asthma, 1997, 34(4):313-319. doi: 10.3109/02770909709067221. doi: 10.3109/02770909709067221 URL
[15]	David B, Bafadhel M, Koenderman L, et al. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax, 2021, 76(2):188-195. doi: 10.1136/thoraxjnl-2020-215167. doi: 10.1136/thoraxjnl-2020-215167 URL
[16]	Yun JH, Lamb A, Chase R, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol, 2018, 141(6):2037-2047. doi: 10.1016/j.jaci.2018.04.010. doi: 10.1016/j.jaci.2018.04.010 URL
[17]	Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med, 2016, 193(9):965-974. doi: 10.1164/rccm.201509-1869OC. doi: 10.1164/rccm.201509-1869OC URL
[18]	Prins HJ, Duijkers R, Lutter R, et al. Blood eosinophilia as a marker of early and late treatment failure in severe acute exacer-bations of COPD. Respir Med, 2017, 131:118-124. doi: 10.1016/j.rmed.2017.07.064. doi: 10.1016/j.rmed.2017.07.064 URL
[19]	Benson VS, Hartl S, Barnes N, et al. Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis. Eur Respir J, 2022, 59(1):2004590. doi: 10.1183/13993003.04590-2020. doi: 10.1183/13993003.04590-2020 URL
[20]	Kay AB. The early history of the eosinophil. Clin Exp Allergy, 2015, 45(3):575-582. doi: 10.1111/cea.12480. doi: 10.1111/cea.12480 pmid: 25544991
[21]	Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nat Med, 2013, 19(8):977-979. doi: 10.1038/nm.3300. doi: 10.1038/nm.3300 pmid: 23921745
[22]	Spits H, Artis D, Colonna M, et al. Innate lymphoid cells: a proposal for uniform nomenclature. Nat Rev Immunol, 2013, 13(2):145-149. doi: 10.1038/nri3365. doi: 10.1038/nri3365 URL
[23]	Hassani M, van Staveren S, van Grinsven E, et al. Characteri-zation of the phenotype of human eosinophils and their progenitors in the bone marrow of healthy individuals. Haematologica, 2020, 105(2):e52-e56. doi: 10.3324/haematol.2019.219048. doi: 10.3324/haematol.2019.219048 URL
[24]	Smit JJ, Lukacs NW. A closer look at chemokines and their role in asthmatic responses. Eur J Pharmacol, 2006, 533(1-3):277-288. doi: 10.1016/j.ejphar.2005.12.064. doi: 10.1016/j.ejphar.2005.12.064 URL
[25]	Moqbel R, Levi-Schaffer F, Kay AB. Cytokine generation by eosinophils. J Allergy Clin Immunol, 1994, 94(6 Pt 2):1183-1188. doi: 10.1016/0091-6749(94)90330-1. doi: 10.1016/0091-6749(94)90330-1 URL
[26]	Davoine F, Lacy P. Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. Front Immunol, 2014, 5:570. doi: 10.3389/fimmu.2014.00570. doi: 10.3389/fimmu.2014.00570
[27]	George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis, 2016, 7(1):34-51. doi: 10.1177/2040622315609251. doi: 10.1177/2040622315609251 pmid: 26770668
[28]	Doyle AD, Mukherjee M, LeSuer WE, et al. Eosinophil-derived IL-13 promotes emphysema. Eur Respir J, 2019, 53(5):1801291. doi: 10.1183/13993003.01291-2018. doi: 10.1183/13993003.01291-2018 URL
[29]	Noël A, Perveen Z, Xiao R, et al. Mmp12 Is Upregulated by in utero Second-Hand Smoke Exposures and Is a Key Factor Contributing to Aggravated Lung Responses in Adult Emphysema, Asthma, and Lung Cancer Mouse Models. Front Physiol, 2021, 12:704401. doi: 10.3389/fphys.2021.704401. doi: 10.3389/fphys.2021.704401 URL
[30]	Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol, 2016, 16(11):676-689. doi: 10.1038/nri.2016.95. doi: 10.1038/nri.2016.95 pmid: 27640624
[31]	Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J, 2019, 54(2):1900651. doi: 10.1183/13993003.00651-2019. doi: 10.1183/13993003.00651-2019 URL
[32]	Brown HM. Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum. Lancet, 1958, 2(7059):1245-1247. doi: 10.1016/s0140-6736(58)91385-0. doi: 10.1016/s0140-6736(58)91385-0
[33]	Singh D. Blood eosinophil counts in chronic obstructive pulmonary disease: A biomarker of inhaled corticosteroid effects. Tuberc Respir Dis (Seoul), 2020, 83(3):185-194. doi: 10.4046/trd.2020.0026. doi: 10.4046/trd.2020.0026 URL
[34]	Camp J, Cane JL, Bafadhel M. Shall we focus on the eosinophil to guide treatment with systemic corticosteroids during acute exacerbations of COPD?:PRO. Med Sci (Basel), 2018, 6(3):74. doi: 10.3390/medsci6030074. doi: 10.3390/medsci6030074
[35]	Beeh KM, Beier J, Kornmann O, et al. Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. Chest, 2003, 123(3):778-783. doi: 10.1378/chest.123.3.778. doi: 10.1378/chest.123.3.778 pmid: 12628878
[36]	Hospers JJ, Schouten JP, Weiss ST, et al. Asthma Attacks with Eosinophilia Predict Mortality from Chronic Obstructive Pulmonary Disease in a General Population Sample. Am J Respir Crit Care Med, 1999, 160(6):1869-1874. doi: 10.1164/ajrccm.160.6.9811041. doi: 10.1164/ajrccm.160.6.9811041 URL
[37]	Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med, 2012, 186(1):48-55. doi: 10.1164/rccm.201108-1553OC. doi: 10.1164/rccm.201108-1553OC URL
[38]	Singh D, Agusti A, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J, 2019, 53(5):1900164. doi: 10.1183/13993003.00164-2019. doi: 10.1183/13993003.00164-2019 URL
[39]	Casanova C, Celli BR, de-Torres JP, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J, 2017, 50(5):1701162. doi: 10.1183/13993003.01162-2017. doi: 10.1183/13993003.01162-2017 URL
[40]	Dinh-Xuan AT, Brusselle G. FENO as a biomarker guide for inhaled corticosteroid step down in patients with mild-to-moderate well-controlled asthma. Eur Respir J, 2020, 55(5):2001319. doi: 10.1183/13993003.01319-2020. doi: 10.1183/13993003.01319-2020 URL
[41]	Çolak Y, Afzal S, Nordestgaard BG, et al. Combined value of exhaled nitric oxide and blood eosinophils in chronic airway disease: the Copenhagen General Population Study. Eur Respir J, 2018, 52(2):1800616. doi: 10.1183/13993003.00616-2018. doi: 10.1183/13993003.00616-2018 URL
[42]	Aldridge RE, Hancox RJ, Cowant JO, et al. Eosinophils and eosinophilic cationic protein in induced sputum and blood: effects of budesonide and terbutaline treatment. Ann Allergy Asthma Immunol, 2002, 89(5):492-497. doi: 10.1016/s1081-1206(10)62087-x. doi: 10.1016/s1081-1206(10)62087-x URL
[43]	Van Bragt JJMH, Vijverberg SJH, Weersink EJM, et al. Blood biomarkers in chronic airways diseases and their role in diagnosis and management. Expert Rev Respir Med, 2018, 12(5):361-374. doi: 10.1080/17476348.2018.1457440. doi: 10.1080/17476348.2018.1457440 URL
[44]	Saeed MI, Eklöf J, Achir I, et al. Use of inhaled corticosteroids and the risk of developing type 2 diabetes in patients with chronic obstructive pulmonary disease. Diabetes Obes Metab, 2020, 22(8):1348-1356. doi: 10.1111/dom.14040. doi: 10.1111/dom.14040 URL
[45]	Lodise TP, Li J, Gandhi HN, et al. Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies. Int J Chron Obstruct Pulmon Dis, 2020, 15:2889-2900. doi: 10.2147/COPD.S269637. doi: 10.2147/COPD.S269637 URL
[46]	Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J, 2007, 29(5):906-913. doi: 10.1183/09031936.00146306. doi: 10.1183/09031936.00146306 pmid: 17301099
[47]	Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med, 2018, 6(2):117-126. doi: 10.1016/S2213-2600(18)30006-7. doi: 10.1016/S2213-2600(18)30006-7 URL
[48]	Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2020[EB/OL].[2021-12-29]. https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf.
[49]	Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax, 2016, 71(2):118-125. doi: 10.1136/thoraxjnl-2015-207021. doi: 10.1136/thoraxjnl-2015-207021 pmid: 26585525
[50]	Hart TK, Cook RM, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol, 2001, 108(2):250-257. doi: 10.1067/mai.2001.116576. doi: 10.1067/mai.2001.116576 URL
[51]	Dasgupta A, Kjarsgaard M, Capaldi D, et al. A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis. Eur Respir J, 2017, 49(3):1602486. doi: 10.1183/13993003.02486-2016. doi: 10.1183/13993003.02486-2016 URL
[52]	Shahlavi-Monavvar P, Mobasher-Jannat A. Mepolizumab for Eosinophilic COPD. N Engl J Med, 2018, 378(7):681. doi: 10.1056/NEJMc1715454. doi: 10.1056/NEJMc1715454
[53]	Xia Y, Li W, Shen H. Mepolizumab for Eosinophilic COPD. N Engl J Med, 2018, 378(7):680-681. doi: 10.1056/NEJMc1715454. doi: 10.1056/NEJMc1715454 URL
[54]	Pavord ID. Biologics and chronic obstructive pulmonary disease. J Allergy Clin Immunol, 2018, 141(6):1983-1991. doi: 10.1016/j.jaci.2018.04.020. doi: S0091-6749(18)30636-5 pmid: 29729941
[55]	Ghazi A, Trikha A, Calhoun WJ. Benralizumab—a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity—a novel approach for the treatment of asthma. Expert Opin Biol Ther, 2012, 12(1):113-118. doi: 10.1517/14712598.2012.642359. doi: 10.1517/14712598.2012.642359 URL
[56]	Brightling CE, Bleecker ER, Panettieri RA Jr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med, 2014, 2(11):891-901. doi: 10.1016/S2213-2600(14)70187-0. doi: 10.1016/S2213-2600(14)70187-0 URL
[57]	Donovan T, Milan SJ, Wang R, et al. Anti-IL-5 therapies for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2020, 12(12):CD013432. doi: 10.1002/14651858.CD013432. doi: 10.1002/14651858.CD013432
[58]	May RD, Fung M. Strategies targeting the IL-4/IL-13 axes in disease. Cytokine, 2015, 75(1):89-116. doi: 10.1016/j.cyto.2015.05.018. doi: 10.1016/j.cyto.2015.05.018 URL
[59]	Fieldes M, Bourguignon C, Assou S, et al. Targeted therapy in eosinophilic chronic obstructive pulmonary disease. ERJ Open Res, 2021, 7(2):00437-2020. doi: 10.1183/23120541.00437-2020. doi: 10.1183/23120541.00437-2020
[60]	Weissler JC, Adams TN. Eosinophilic Chronic Obstructive Pulmonary Disease. Lung, 2021, 199(6):589-595. doi: 10.1007/s00408-021-00492-0. doi: 10.1007/s00408-021-00492-0 URL